Zenotrex Medico Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-07-2024
- Paid Up Capital ₹ 1.00 M
as on 16-07-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 837.40%
(FY 2022)
- Profit 711.42%
(FY 2022)
- Ebitda 438.72%
(FY 2022)
- Net Worth 423.21%
(FY 2022)
- Total Assets 669.20%
(FY 2022)
About Zenotrex Medico
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Usha Devi and Amit Sharma serve as directors at the Company.
- CIN/LLPIN
U33119HR2020PTC087347
- Company No.
087347
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Jul 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Zenotrex Medico Private Limited offer?
Zenotrex Medico Private Limited offers a wide range of products and services, including Hospital and Medical Furniture, Hospital and Medical Cabinet, Autoclaves, Sterilizers & Incubators, Laboratory Autoclave & Sterilizers, Laboratory & Pharmaceutical Ovens, Industrial Autoclave & Sterilizers, Laboratory & Lab Equipment, Laboratory Bath, Crusher, Shredder & Presses, Shredding Machine.
Who are the key members and board of directors at Zenotrex Medico?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Usha Devi  | Director | 10-Jul-2020 | Current |
| Amit Sharma | Director | 10-Jul-2020 | Current |
Financial Performance of Zenotrex Medico.
Zenotrex Medico Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 837.4% increase. The company also saw a substantial improvement in profitability, with a 711.42% increase in profit. The company's net worth Soared by an impressive increase of 423.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Zenotrex Medico?
In 2022, Zenotrex Medico had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Zenotrex Medico?
Zenotrex Medico has a workforce of 0 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Zenotrex Medico, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Zenotrex Medico's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
